You are viewing a single comment's thread from:
RE: Spark Therapeutics Announces First-of-their-kind Programs to Improve Patient Access to LUXTURNA™ (voretigene neparvovec-rzyl), a One-time Gene Therapy Treatment
Maybe developers needs to put together an accounting for how much that it cost to develop and be reimbursed for that amount with an appropriate markup. Then that cannot be used as an excuse for withholding drugs from people.